FDA grants breakthrough therapy designation for Roche ’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis

Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to Actemra/RoActemra ® (tocilizumab) for giant cell arteritis (GCA), a chronic, potentially life-threatening autoimmune condition.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news